The European Medicines Agency (EMA) has issued its monthly report which includes a section highlighting the risks of venous thromboembolism (VTE) for women who take Yaz and any other oral contraceptive that contains drospirenone.
The EMA Pharmacovigilance Working Party (PhVWP) reviewed all available data including recent publications and information regarding the risks of VTEs associated with drospirenone. A VTE is when a blood clot occurs in a vein which can then travel through the bloodstream to organs and the brain, potentially causing serious injury or death.
The PhVWP found that drospirenone-containing oral contraceptives like YAZ and Yasmin have a higher risk of VTEs than other similar oral contraceptives. Read the entire report here: European Medical Agency Monthly Report – Yasmin
If you or a loved one has taken Yaz or Yasmin and experience negative effects, click here to learn more about the Brandi Law Firm Yaz Attorneys.